News
ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC
Gilead lays down a marker for AZ and Daiichi Sankyo to follow as Trodelvy scores in first-line treatment of triple-negative breast cancer (TNBC).
Sunday 15 June 2025
